ISTA Pharmaceuticals Receives FDA Approval For BROMDAY™

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), announced the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for BROMDAY™ (bromfenac ophthalmic solution) 0.09% as a once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction...

Full Story →